Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of zicronapine, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of zicronapine; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of zicronapine, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.

Abstract: Speech fluency evaluation and feedback tools are described. A computing device such as a smartphone may be used to collect speech (and/or other data). The collected data may be analyzed to detect various speech events (e.g., stuttering) and feedback may be generated and provided based on the detected speech events. The collected data may be used to generate a fluency score or other performance metric associated with speech. Collected data may be provided to a practitioner such as a speech therapist or physician for improved analysis and/or treatment.

Abstract: A smart dosing device includes: a supply pathway having a compartment that is able to house multiple discrete doses of a substance; at least one sensor that captures identifying information related to the substance; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: retrieving a discrete dose from a storage cavity of the smart dosing device; and providing the discrete dose via an outlet port of the device. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing multiple discrete doses of a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device including the unique identifier and the unique cartridge identifier.

Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of metformin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of metformin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of metformin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of vortioxetine, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of vortioxetine; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of vortioxetine, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of brexpiprazole, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of brexpiprazole; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of brexpiprazole, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of lurasidone, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of lurasidone; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of lurasidone, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of sildenafil citrate, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of sildenafil citrate; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of sildenafil citrate, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of blonanserin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of blonanserin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of blonanserin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of trazodone, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of trazodone; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of trazodone, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; a specified dose of olanzapine; and a specified dose of metformin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, a specified dose of olanzapine, and a specified dose of metformin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, twice per day, an ingredient mixture including: a flavoring agent; a lubricant; a specified dose of olanzapine; and a specified dose of metformin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).

Abstract: A smart dosing device includes: a supply pathway having a compartment that is able to house a plurality of discrete doses of a particular substance; at least one sensor that captures identifying information related to the particular substance; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: retrieving a discrete dose from a storage cavity of the smart dosing device; and providing the discrete dose via an outlet port of the smart dosing device. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing multiple discrete doses of a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device, the usage information comprising: the unique identifier and the unique cartridge identifier.

Abstract: A self-administered tester for infection may include a sample collection element for receiving fluid samples including bodily fluids. The sample collection elements may provide at least a portion of a collected sample to one or more evaluation elements. Each evaluation element may determine whether some evaluation criteria have been satisfied. Result indicators may provide visual indicators showing whether the evaluation criteria were satisfied. The self-administered tester may test for a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection using evaluators associated with the Immunoglobulin G (IgG) antibody and the Immunoglobulin M (IgM) antibody.

Abstract: A smart inhaler device includes: a flow pathway having a cartridge receptacle that is able to house a cartridge, flow meter, pump, and vaporizer; a wireless communication module; and at least one sensor that captures identifying information related to the cartridge. A method of providing a measured dose using a smart inhaler device includes: enabling dosing; measuring a provided dose; and disabling dosing. A smart inhaler system includes: a smart inhaler device; a user device; and a server.

Abstract: A smart dosing device includes: a flow pathway having a cartridge receptacle that is able to house a cartridge; at least one sensor that captures identifying information related to the cartridge; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: enabling dosing; measuring a provided dose; and disabling dosing. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device, the usage information including: the unique identifier and the unique cartridge identifier.